Mads Daugaard
Co-founder, President & Chief Scientific Officer Rakovina Therapeutics, Inc.
Seminars
• Bringing together academic founders and investors to explore what makes DDR programs fundable
• Examining licensing, MTA bottlenecks, and funding models across early and late-stage ventures
• Offering insights into risk assessment, strategic partnerships, and scaling innovation
• See Rakovina Therapeutic’s journey of pivoting a DDR-focused biotech to a fully AI-driven discovery model
• Illustrating case studies of AI-designed DDR programs advancing through preclinical lead selection
• Evaluating predictive accuracy, translational potential, and long-term impact of AI on drug development
• Sharing real-world stories from scientists who launched successful DDR-focused startups
• Discussing practical steps for IP strategy, equity negotiations, and CEO recruitment
• Highlighting university-industry collaboration models that accelerate translation
